47.65
-0.16(-0.33%)
Currency In USD
| Previous Close | 47.81 |
| Open | 47.84 |
| Day High | 48.31 |
| Day Low | 47.07 |
| 52-Week High | 93.77 |
| 52-Week Low | 27.66 |
| Volume | 630,666 |
| Average Volume | 1.61M |
| Market Cap | 6.24B |
| PE | -9.82 |
| EPS | -4.85 |
| Moving Average 50 Days | 45.11 |
| Moving Average 200 Days | 39.2 |
| Change | -0.16 |
If you invested $1000 in Vaxcyte, Inc. (PCVX) since IPO date, it would be worth $1,822.18 as of December 25, 2025 at a share price of $47.65. Whereas If you bought $1000 worth of Vaxcyte, Inc. (PCVX) shares 3 years ago, it would be worth $1,049.33 as of December 25, 2025 at a share price of $47.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
GlobeNewswire Inc.
Dec 08, 2025 12:00 PM GMT
Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
GlobeNewswire Inc.
Sep 30, 2025 12:30 PM GMT
New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte’s Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates SAN CARLOS, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, I
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
GlobeNewswire Inc.
Sep 03, 2025 11:30 AM GMT
VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal Disease (IPD) Company Intends to Release Topli